Sunshine Lake Pharma Co., Ltd. is a China-based pharmaceutical company focused on the research, development, manufacturing, and commercialization of medicines across infectious diseases, metabolic disorders, and cardiovascular therapy areas. The company is associated with the HEC Group ecosystem, with operations that include API and finished-dose capabilities and participation in both domestic and international markets. Its portfolio and pipeline span small-molecule antivirals and biologics, with activity in hepatitis B and C, insulin therapies for diabetes, and hypertension treatments, reflecting an emphasis on high-burden public health needs. Sunshine Lake Pharma Co., Ltd. contributes to China’s drug innovation and supply chain through integrated R&D and large-scale production, supported by an extensive intellectual property footprint and regulatory-facing development programs. Within the broader healthcare sector, the company plays a role as both a developer and manufacturer, supplying products and technologies that reach hospitals, pharmacies, and healthcare institutions. Its positioning underscores the growing role of Chinese pharmaceutical firms in advancing therapeutics and expanding access to essential medicines across regional and global markets.